

Yingyu Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7776115/publications.pdf>

Version: 2024-02-01

39
papers

561
citations

840776

11
h-index

642732

23
g-index

40
all docs

40
docs citations

40
times ranked

749
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring therapeutic potentials of baicalin and its aglycone baicalein for hematological malignancies. <i>Cancer Letters</i> , 2014, 354, 5-11.	7.2	102
2	Down-regulation of the PI3K/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 48.	8.6	59
3	Platelet Gene Therapy by Lentiviral Gene Delivery to Hematopoietic Stem Cells Restores Hemostasis and Induces Humoral Immune Tolerance in FIXnull Mice. <i>Molecular Therapy</i> , 2014, 22, 169-177.	8.2	53
4	Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells. <i>Blood</i> , 2014, 123, 395-403.	1.4	50
5	DIGE-based proteomic analysis identifies nucleophosmin/B23 and nucleolin C23 as over-expressed proteins in relapsed/refractory acute leukemia. <i>Leukemia Research</i> , 2011, 35, 1087-1092.	0.8	35
6	Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062071989981.	2.5	29
7	Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice. <i>Blood Advances</i> , 2019, 3, 3099-3110.	5.2	28
8	Emodin enhances ATRA-induced differentiation and induces apoptosis in acute myeloid leukemia cells. <i>International Journal of Oncology</i> , 2014, 45, 2076-2084.	3.3	26
9	Decreased expression of nucleophosmin/B23 increases drug sensitivity of adriamycin-resistant Molt-4 leukemia cells through mdr-1 regulation and Akt/mTOR signaling. <i>Immunobiology</i> , 2015, 220, 331-340.	1.9	21
10	The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity. <i>Blood</i> , 2016, 127, 1346-1354.	1.4	21
11	Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 2061-2073.	1.6	20
12	Synergistic Effect of Baicalin and Adriamycin in Resistant HL-60/ADM Leukaemia Cells. <i>Cellular Physiology and Biochemistry</i> , 2017, 43, 419-430.	1.6	11
13	Integrated bioinformatics analysis of the crucial candidate genes and pathways associated with glucocorticoid resistance in acute lymphoblastic leukemia. <i>Cancer Medicine</i> , 2020, 9, 2918-2929.	2.8	11
14	Integration of bioinformatics and experiments to identify TP53 as a potential target in Emodin inhibiting diffuse large B cell lymphoma. <i>Biomedicine and Pharmacotherapy</i> , 2018, 107, 226-233.	5.6	10
15	Platelet desialylation and TFH cells—the novel pathway of immune thrombocytopenia. <i>Experimental Hematology and Oncology</i> , 2021, 10, 21.	5.0	10
16	Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 283-293.	2.5	9
17	Discovery of FZU-03,010 as a self-assembling anticancer amphiphile for acute myeloid leukemia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1007-1011.	2.2	9
18	Discovery of novel negletein derivatives as potent anticancer agents for acute myeloid leukemia. <i>Chemical Biology and Drug Design</i> , 2018, 91, 924-932.	3.2	9

#	ARTICLE	IF	CITATIONS
19	Doxorubicin/Nucleophosmin Binding Protein-Conjugated Nanoparticle Enhances Anti-leukemia Activity in Acute Lymphoblastic Leukemia Cells in vitro and In vivo. <i>Frontiers in Pharmacology</i> , 2021, 12, 607755.	3.5	9
20	Design and synthesis of various quinizarin derivatives as potential anticancer agents in acute T lymphoblastic leukemia. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1362-1369.	3.0	8
21	E35 ablates acute leukemia stem and progenitor cells in vitro and in vivo. <i>Journal of Cellular Physiology</i> , 2020, 235, 8023-8034.	4.1	8
22	In vivo enrichment of genetically manipulated platelets for murine hemophilia B gene therapy. <i>Journal of Cellular Physiology</i> , 2021, 236, 354-365.	4.1	7
23	Effect of nucleolin on adriamycin resistance via the regulation of Bcl-2 expression in Burkitt's lymphoma cells. <i>Journal of Cellular Physiology</i> , 2019, 234, 22666-22674.	4.1	3
24	Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice. <i>Blood Advances</i> , 2020, 4, 2272-2285.	5.2	3
25	In Vitro Investigation of the Cytotoxic Activity of Emodin 35 Derivative on Multiple Myeloma Cell Lines. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-11.	1.2	3
26	Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity. <i>Blood Advances</i> , 2021, 5, 1224-1238.	5.2	3
27	Association of Platelet Desialylation and Circulating Follicular Helper T Cells in Patients With Thrombocytopenia. <i>Frontiers in Immunology</i> , 2022, 13, 810620.	4.8	3
28	Adriamycin/Nucleophosmin Binding Protein-Conjugated Nanoparticle (ADR-PMs-NPMBP) Enhances Anti-Leukemia Activities of Adriamycin in Acute Lymphoblastic Leukemia Cells. <i>Blood</i> , 2020, 136, 16-16.	1.4	1
29	Inhibition Effects of baicalin on Lymphoma Cell Line CA46 in Vitro and in Vivo. <i>Blood</i> , 2008, 112, 5053-5053.	1.4	0
30	Targeting FVIII Expression to Platelets Induces Immune Tolerance in Hemophilia A Mice with or without Pre-Existing Anti-FVIII Immunity. <i>Blood</i> , 2011, 118, 4170-4170.	1.4	0
31	Lentivirus-Mediated Platelet Gene Therapy Corrects Bleeding Diathesis and Induces Immune Tolerance in Murine Hemophilia B Mice. <i>Blood</i> , 2012, 120, 1101-1101.	1.4	0
32	In Vivo Selection Of Genetically Manipulated Hematopoietic Stem Cells For Platelet Gene Therapy Of Hemophilia A. <i>Blood</i> , 2013, 122, 2329-2329.	1.4	0
33	Decreased Expression of Nucleophosmin/B23 Increases Drug Sensitivity of Adriamycin-Resistant Lymphoblastic Leukemia Molt-4 Cells through mdr-1 Regulation. <i>Blood</i> , 2014, 124, 5229-5229.	1.4	0
34	The Immunogenicity of Platelet-Derived FVIII in Hemophilia a Mice with or without Pre-Existing Anti-FVIII Immunity. <i>Blood</i> , 2014, 124, 2809-2809.	1.4	0
35	Immune Tolerance Developed in Platelet-Targeted FVIII Gene Therapy in Hemophilia Mice Is CD4+ T Cell-Mediated. <i>Blood</i> , 2015, 126, 1071-1071.	1.4	0
36	E35, a Novel Analog of Emodin, Selectively Eliminates Acute Leukemia Stem and Progenitor Cells. <i>Blood</i> , 2016, 128, 5213-5213.	1.4	0

#	ARTICLE	IF	CITATIONS
37	In Vivo Enrichment of Genetically Manipulated Platelets for Murine Haemophilia B Gene Therapy. Blood, 2018, 132, 3483-3483.	1.4	0
38	Induction of Activated T Follicular Helper Cells Is Critical for Anti-FVIII Inhibitor Development in Hemophilia a Mice. Blood, 2019, 134, 92-92.	1.4	0
39	Fludarabine in Combination with Busulfan As Pretransplant Conditioning for Platelet Gene Therapy in Murine Hemophilia a with Inhibitors. Blood, 2019, 134, 1108-1108.	1.4	0